A practical reference on Photo-oxidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Wide nose – To narrow a too-wide nose, the plastic surgeon cuts, contours, and rearranges the craniofacial bones to achieve the desired functional and aesthetic outcome of a narrower, straighter nose. To leave no visible, surgical scars upon the new nose, the surgeon effects the osteotome (bone chisel) incisions to the nasal bones beneath the facial skin. Illustration 1: The surgeon cuts the excessively wide bones of the upper nasal dorsum (violet) with an osteotome (bone chisel), then detaches, corrects, and relocates them inwards, to a position, between the ocular orbits (red), that narrows the width of the nasal dorsum. Illustration 2: The surgeon chisels two cuts (incisions) to the nasal bones, each incision begins at the nasal cavity. The first incision begins at the yellow dot and extends upwards, along the green arrow, until meeting the zig-zag line (red). The second incision begins at the blue dot and extends upwards, along the black arrow, until meeting the zig-zag line (red). Once cut and loosened from the face, the nasal bone pieces are corrected, then pushed inwards and re-set, thus narrowing the nose.
== Advertising == A&W does not do national advertising; the primary factor for such being the lack of restaurants in certain parts of the United States. Its first attempt at doing a national television commercial was on June 16, 1969, when it booked for a slot on NBC's Monday Night at the Movies to advertise take-home gallons of root beer. In 1976, A&W Restaurants participated in the Easter Seals Telethon, where money from large root beer mugs was collected by the local restaurant on behalf of the TV station broadcasting the telethon in the area. In 1997, the chain adopted All American Food as its slogan in order to achieve widespread brand recognition. The chain increased its marketing budget in February 2000, eyeing for a new line of burgers in January 2001. For the summer of 2007, the chain launched the Moove to American campaign, which was created to counter competing chains relying exclusively on foreign beef; the campaign started on June 28 with a stunt featuring 35 cows sent on a barge to the Statue of Liberty. The aim was to petition the National Cattlemen's Beef Association to support consumption of U.S. beef. There was also a campaign to set up a new custom burger, with the winner heading over to Louisville to work for its serving in restaurants. A grassroots partnership with Green Bay Packers receiver Greg Jennings began in 2009, where Papa Burgers were sold at a price of 85 cents in Green Bay restaurants if Jennings made a touchdown. Due to its success, the campaign expanded to include all of Wisconsin in 2010.
== Social initiatives == IDLO is a long-time sponsor of various endurance and outdoor events, including Gorgany Race, the Night Chornohora Marathon, Stezhkamy Heroiv, and Spartan Race. The company also partners with educational camps organized by the Ukrainian national scouting organization Plast. Since 2020, IDLO has led an environmental program called “Leave No Trace”, to improve waste management in the Ukrainian mountains. The company accepts used doypacks for recycling, including those from other manufacturers. Following the full-scale Russian invasion of Ukraine in 2022, company co-founders Mykhaylo Temper and Serhii Andrieiev joined the Armed Forces of Ukraine.
Sources: en.wikipedia.org
=== Physicochemical factors affecting carbon nanotube toxicity === Numerous studies have identified key physicochemical properties of carbon nanotubes (CNTs) that influence their biological interactions and toxicological profiles in both in vitro and in vivo systems: Aspect ratio, length, and rigidity: Long and rigid CNTs exhibit increased biopersistence and are strongly associated with fibrogenesis, through the activation of the Smad2/3 and ERK1/2 signaling pathways. Their high aspect ratio and fiber-like morphology, reminiscent of asbestos, can impair macrophage-mediated clearance, and induce inflammation, fibrotic tissue remodeling, granuloma formation, and even DNA damage. Multi-walled carbon nanotubes (MWCNTs) with lengths ranging from approximately 0.5 to 10 μm have been implicated in severe pulmonary conditions, including asbestosis-like fibrosis and mesothelioma. Similarly, single-walled carbon nanotubes (SWCNTs) exceeding 10 μm in length can induce granulomatous lesions. In contrast, shorter SWCNTs—particularly those under 300 nm and well-dispersed—are more readily cleared from the body via renal and biliary excretion pathways. These shorter, purified SWCNTs have demonstrated significantly reduced inflammatory and cytotoxic responses and, to date, lack conclusive evidence of carcinogenicity. Aggregation state: The aggregation state of CNTs refers to their propensity to cluster into bundles or agglomerates, primarily driven by van der Waals forces and electrostatic interactions.
=== 26 July === Russian forces captured the village of Lozuvatske in Donetsk Oblast, 24 kilometers east of Pokrovsk. The FSB announced the arrest of a suspect in the 24 July car bombing in Moscow who had been extradited from Turkey, claiming that he was a Russian national who carried out the attack on behalf of Ukrainian intelligence. Explosions were reported at Saky airfield in Crimea, and a drone attack on Sevastopol was reported. Russian authorities claimed that 21 drones were shot down over Bryansk Oblast.
== Further reading == Lederberg, Joshua; McCray, Alexa T. (April 2, 2001). "Commentary: 'Ome Sweet 'Omics — A Genealogical Treasury of Words". The Scientist. 15 (7): 8. Retrieved 1 June 2014. Hotz, Robert Lee (13 August 2012). "Here's an Omical Tale: Scientists Discover Spreading Suffix". The Wall Street Journal.
== Pharmacodynamics == CPA has antiandrogenic activity, progestogenic activity, weak partial glucocorticoid activity, weak steroidogenesis inhibitor activity, and agonist activity at the pregnane X receptor. It has no estrogenic or antimineralocorticoid activity. In terms of potency, CPA is described as a highly potent progestogen, a moderately potent antiandrogen, and a weak glucocorticoid.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.